The full-year financial results for the fiscal year ending April 2026 show sales figures that are unknown, with operating profits in the U.S., Europe, and Japan being either positive or negative. The medium-term plan aims for increased sales by April 2027, with gastrointestinal field driving growth. Progress in the U.S. and Europe, as well as organizational changes, are also reported.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7777","jir_company_name":"Three-D Matrix Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/7777-20260717-01.pdf","jir_short_summary":"The full-year financial results for the fiscal year ending April 2026 show sales figures that are unknown, with operating profits in the U.S., Europe, and Japan being either positive or negative. The medium-term plan aims for increased sales by April 2027, with gastrointestinal field driving growth. Progress in the U.S. and Europe, as well as organizational changes, are also reported.","jir_summary":"### Performance Overview\nThe financial results for the fiscal year ending April 2026 show an approximately 30% increase in Q4 due to rising sales and new account openings in the U.S. Europe generally progressed according to budget, particularly in the gastrointestinal field, turning to profit. Meanwhile, Japan experienced a loss due to headquarters common costs. Overall, the company maintains high growth, while strengthening organizational structures and making strategic investments for future expansion.\n\n### Future Outlook and Strategy\nThe medium-term management plan sets a high-growth sales target for FY2027, with a focus on expanding the gastrointestinal field as the main driver. In the U.S., gastrointestinal penetration remains low at 15\u201320%, offering substantial growth potential. In Europe, new needs in otolaryngology and urology are expected to generate sustainable growth. The company is also revising its organizational structure and strengthening sales operations, with an increase in employees planned for FY2027.","jir_financial_highlights":"Sales for Q4 of FY2026 ending April: Unknown (Approximately 30% increase (U.S.))\nEuropean operating profit: Profit (Unknown)\nJapanese operating profit: Loss (Unknown)","jir_category":"","jir_hashtags":"#Three-DMatrix, #Earnings, #JapaneseStocks","jir_key_figures":"Sales: Unknown (FY2026 Q4 data not provided)\nU.S. Q4 sales increase: approximately 30%\nEuropean operating profit: profit\nJapanese operating profit: loss\nNumber of employees: 129 (end of FY2026) \u2192 planned 139 (end of FY2027)","jir_meta_title":"\u3010Three-D Matrix\u30112026 Full-Year Financial Results and Medium-Term Plan \uff5c July 2026","jir_meta_description":"Detailed information on the 2026 full-year financial results and medium-term management plan of Three-D Matrix Corporation. An overview of sales, profits, and future growth strategies.","jir_og_title":"\u3010Three-D Matrix\u30112026 Financial Results and Medium-Term Plan \uff5c July 2026","jir_og_description":"An explanation of key points for the 2026 full-year financial results and medium-term plan. Details on sales, profit trends, and future business prospects for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56804,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-82592","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n